| Symbol | RHHBF |
|---|---|
| Name | ROCHE HOLDING LTD |
| Sector | UNDEFINED |
| Region | Europe |
| Industry | - |
| Address | 4070 Switzerland Grenzacherstrasse 124 |
| Telephone | +41 61 688 1111 |
| Fax | — |
| — | |
| Website | http://www.roche.com |
| Incorporation | CH |
| Incorporated On | 1896 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | KPMG Accountants N.V.; |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: SIX Swiss Exchange |
| CIK | 0000896566 |
| Description | Founded in1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the worlds largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. In recognizing our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. Additional info from OTC: |
FDA Approves Genentech’s Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
Read moreGenentech Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive Lymphomas
Read moreGenentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis
Read moreGenentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025
Read morePositive Phase III Results Show Genentech’s Giredestrant Significantly Improved Progression-Free Survival in ER-positive Advanced Breast Cancer
Read moreNew Data Show Genentech’s Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
Read moreTen-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
Read moreOTCQX symbol attribute type Exchange was changed. Previous value: -. New value: OTCQX.
Read moreOTCQX symbol attribute type Exchange was changed. Previous value: -. New value: OTCQX.
Read moreOTCQX symbol attribute type Exchange was changed. Previous value: -. New value: OTCQX.
Read more